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S U M M A R Y
This is a perspectives piece on the central role of diagnostics for a truly holistic approach against
gastrointestinal (GI) parasitic diseases. This article was motivated by a recent review in the International
Journal of Infectious Diseases, where Absar Alum and colleagues (September 2010) reviewed the global
burden, key transmission pathways, current tools and strategies, and provided their vision of a holistic
approach to control GI protozoan and helminthic infections in humans. We argue that, as the success of
multiple rounds of national deworming campaigns are actualized in various parts of the world,
diagnostics become vital to achieve successful elimination and to aid pharmacovigilance against
emerging pathogen resistance to the limited deworming pharmacopoeia.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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journa l homepage: www.e lsev ier .com/ locate / i j idIn the September 2010 issue of the International Journal of
Infectious Diseases, Absar Alum and colleagues reviewed the global
burden, key transmission pathways, current tools and strategies,
and provided a vision of a holistic approach to control gastroin-
testinal (GI) protozoan and helminthic infections in humans.1
Indeed, the control, prevention of associated morbid sequelae, and
eventual local elimination of GI infections are central to the long-
term public health and socioeconomic aspirations of the tropics
and sub-tropics.2,3 The effects of untreated chronic infections in
marginalized and under served populations are well documented,
ranging from negative birth outcomes, delayed physical and
cognitive development during childhood, and reduced school
attendance and performance of infected children, to diminished
productivity among adults.4–8 However, the pivotal role of
accurate diagnosis at all stages of a control program targeting GI
diseases is often neglected, as is demonstrated in the review by
Alum et al.1 This is particularly true regarding GI nematodes (e.g.,
Ascaris lumbricoides, hookworm, and Trichuris trichiura), as the
global strategy for their control is ‘preventive chemotherapy’, that
is repeated large-scale administration of anthelmintic drugs aimed* Corresponding author. Tel.: +1 215 898 6441; fax: +1 215 898 2124.
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doi:10.1016/j.ijid.2010.10.007to cover at least 75% of all school-aged children deemed to be at
risk of morbidity. Asmultiple rounds of ‘preventive chemotherapy’
are implemented in various parts of the world and start to record
success, we argue that accurate diagnostics are vital to monitor
subtle changes over time, to signal emerging drug resistance, and
to verify whether local elimination has been achieved.9–11
Our position is justiﬁed as follows. Foremost, the paucity of
readily available, rapid, affordable, ﬁeld-adapted, and accurate
diagnostic assays for GI nematodes hinders (1) accurate documen-
tation of their ecological distribution, (2) precise estimation of at-
risk populations and burden of disease, and (3) spatial targeting of
control interventions.10–13 This is because individual testing for
diagnosis, indicated by the presence of eggs in feces, is often not
undertaken based on cost-effectiveness considerations that
recommend large-scale anthelmintic distribution to at-risk
populations without prior diagnosis.5,13 At an early stage of a
control program, when morbidity control is the goal and a large
proportion of the population are indeed infected, such a strategy
makes sense. However, a change in approach from morbidity
control to infection/transmission control is needed as the parasite
biomass and risk of infection are reduced with a growing
proportion of the population being treated unnecessarily, as they
are not infected.10,11 At this stage, deploying diagnostic tools will
help adjust interventions to the changing situation.ses. Published by Elsevier Ltd. All rights reserved.
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such as thewidely used Kato–Katz thick smearmethod, is that they
are based on the detection of helminth eggs in feces, which does
not correlate exactly with adult worm burden, the primary
diagnostic and clinical target.10 While poor sensitivity for low-
intensity infections is particularly problematic, differentiation of
the eggs of different helminths can also lead to low speciﬁcity. The
result is that, if used programmatically, ﬁeld deworming programs
would underestimate prevalence and infection intensity, which
will be of increasing importance as control programs progress.10,11
Clearly, diagnostic assays based on antigen or antibody detection
are required, though a paradigm shift would be needed for them to
be introduced.10,11
When used in clinical trials, current diagnostic tools, because of
their low sensitivity, may overestimate treatment efﬁcacy, thus
potentially missing early signs of drug resistance. Monitoring drug
efﬁcacy is important,14 and although chemotherapeutic options for
GI nematodes appear adequate at present, experience from
veterinary public health shows that drug resistance can easily
occur to all the classes of compounds in current use.15 While
human drug exposure levels are far lower, both individually and in
the community, compared to animals, current compounds have
not necessarily been optimized for human use.3,15–18 Furthermore,
the current armory of anthelmintic drugs is very limited and
virtually no backups exist.16,17
Against this scenario, there is, at present, little or no research
into novel diagnostic approaches. The recent G-ﬁnder reports,19,20
which surveyed 134 major funding organizations involved in
neglected disease product development, found that of the
approximately US$ 34 million spent on GI helminth research
and development (R&D) globally in 2007, less than US$ 0.1 million
was spent on diagnostics (US$ 58 845 for strongyloidiasis and
other intestinal roundworms and US$ 39 980 for schistosomiasis).
In a follow-up report covering 2008 with a larger sample of
funders, there was little if any improvement (US$ 0.24 million out
of US$ 33.1million).21 The reports did not ﬁnd any speciﬁc funding
for GI protozoan diagnostics, but did ﬁnd that US$ 7 million of the
US$ 114 million spent on funding for diarrheal diseases product
R&D in 2007 was directed toward diagnostics, largely for bacterial
infections. Though a much improved sum comparatively, the
imbalance is obvious.
In brief, diagnostics essentially play no role at the onset of a
‘preventive chemotherapy’ campaign where the total at-risk
population is treated as if they were all infected. However with
the progressive reduction in parasite prevalence, and thus
parasite biomass, through multiple rounds of preventive
chemotherapy, the importance of appropriate and improved
diagnostics must be realized and brought to the ﬁeld through
increased R&D and integration into deworming programs.
Without additional funds and greater appreciation for the role
of GI nematode diagnostics, national and global deworming
programs will increasingly face problems in properly switchingfrom morbidity control to infection/transmission control and
ultimately local elimination.
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